Mirjavad Mammadov: Understanding the Thrombotic Paradox of Heparin Therapy
Mirjavad Mammadov, Cardiac Device Specialist at Besan MMC, shared a post on LinkedIn about a recent article by Theodore E. Warkentin et al. published in NEJM, adding:
“Heparin-Induced Thrombocytopenia (HIT): When an Anticoagulant Triggers a Prothrombotic Immune Response
Despite being one of the most widely used anticoagulants, heparin can, in rare cases, trigger a serious immune-mediated complication known as Heparin-Induced Thrombocytopenia (HIT).
The underlying mechanism begins when platelet factor 4 (PF4) binds to heparin, forming complexes that may be recognized as foreign by the immune system.
This can stimulate the production of anti-PF4/heparin IgG antibodies, which bind to platelets through FcγIIa receptors, causing intense platelet activation.
Paradoxically, although platelet counts fall, the major clinical concern is thrombosis rather than bleeding. Activated platelets release additional PF4, amplify thrombin generation, and create a self-perpetuating cycle of platelet activation and clot formation.
Early recognition is critical. In patients with suspected HIT:
- Heparin should be discontinued immediately.
- Alternative non-heparin anticoagulation should be considered.
- Diagnosis combines clinical probability (such as the 4Ts score) with laboratory confirmation.
Understanding the immunopathogenesis of HIT remains essential for clinicians managing anticoagulated patients in both cardiovascular medicine and critical care.
Source:
Warkentin TE, Greinacher A. Platelet-Activating Anti-Platelet Factor 4 Disorders. New England Journal of Medicine (NEJM).
Disclaimer:
This post is intended for educational purposes only and should not be interpreted as medical advice or clinical guidance for individual patients.”
Title: Platelet-Activating Anti–Platelet Factor 4 Disorders
Authors: Theodore E. Warkentin, M.D., Andreas Greinacher, M.D.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB